Drug Trial Radar · NCT02474355
Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
Last checked: Nov 20, 2026Latest source record: Nov 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,017
Actual
Start
Sep 18, 2015
Primary completion
Apr 18, 2019
Study completion Apr 18, 2019
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Jun 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy.
Conditions
- Lung Cancer
Interventions
T790M+ TestingProcedure
If a previous lab report is unavailable, the patient will need to have T790M+ testing.
Baseline Visit Blood & Urine TestingProcedure
Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
Baseline ECGProcedure
ECG to ensure absence of any cardiac abnormality
Visual Slit-Lamp TestingProcedure
Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
AZD9291 DosingDrug
Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From the date of first dose of Osimertinib until the date of death (due to any cause) or last participant contact [up to 43 months]
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From screening to progression follow-up [every 6 weeks +/- 1 week] relative to the date of enrolment until the end of study [up to 43 months]
Locations
201 sites in 16 countries. Site status is shown where the registry gives one.
Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
CABA, Argentina
Research Site
Bedford Park, Australia
Research Site
East Melbourne, Australia
Research Site
Kurralta Park, Australia
Research Site
Randwick, Australia
Research Site
Waratah, Australia
Research Site
Innsbruck, Austria
Research Site
Linz, Austria
Research Site
Salzburg, Austria
Research Site
Vienna, Austria
Research Site
Charleroi, Belgium
Research Site
Edegem, Belgium
Research Site
Leuven, Belgium
Research Site
Barretos, Brazil
Research Site
Belo Horizonte, Brazil
Research Site
Florianópolis, Brazil
Research Site
Ijuí, Brazil
Research Site
Itajaí, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Salvador, Brazil
Research Site
Salvador, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Regina, Saskatchewan, Canada
Research Site
Calgary, Alberta, Canada
Research Site
Burnaby, British Columbia, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
North York, Ontario, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Showing 40 of 201 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.